Dr. Conrad Fernandez, Hon BSc (Genetics), MD, FRCPC
Professor and Head, Division of Pediatric Hematology Oncology, Department of Pediatrics. IWK Health Centre, Halifax, Nova Scotia.
Cross-appointed Departments of Bioethics, Graduate Studies, Medicine.
Chair, Renal Tumors Steering Committee, Children’s Oncology Group
Vice Chair Bioethics Committee, Children’s Oncology Group
Member, Panel on Research Ethics, Secretariat on Responsible Conduct of Research. TriCouncil Policy of Canada. Member.
IWK Health Centre, Dalhousie University
Wilms tumor, ethics
My research interests are in two main spheres of inquiry. The first is in Wilms tumor, the most common renal cancer in childhood. I am the chair the multidisciplinary COG renal tumor committee which designs clinical trials for children with renal tumors across North America and parts of Australia, New Zealand and Europe. The collaborations afforded through the renal tumors committee have allowed a number of clinical and basic science research projects in Wilms tumor. I am also active in empiric research in the field of ethics, in particular the return of genetic results to research participants. I am the Ethics Node lead for the molecular profiling project called PROFYLE, a Terry Fox Research Institute funded Canadian national trial examining high risk pediatric, adolescent and young adult cancers in Canada.
Involvement with BHCRI to date:Dr. Fernandez is a BHCRI Senior Scientist and has presented at a CRTP ILS.
Contact:IWK Health Centre, PO Box 9700, 5850 University Avenue, Halifax, NS, B3K 6R8 Canada
(selected from 59 over last 5 years)
Unguru Y, Bernhardt MB, Berg S, Johnson LM, Pyke-Grimm K, Woodman C, Fernandez CV on behalf of the Children’s Oncology Group Allocation Task Force Position Paper – Chemotherapy and Supportive Care Agents are Essential Medicines for Children with Cancer. Accepted to JAMA Pediatrics.
Iaboni DSM, Chi YY, Dome JS, Fernandez CV. Outcome of Wilms Tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: A report from the Children’s Oncology Group. Pediatric Blood Cancer. Pediatr Blood Cancer. 2019 Jan;66(1):e27430. doi: 10.1002/pbc.27430. Epub 2018 Aug 30. PMID:30160355.
Msaouel1 P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee C, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges CH, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated recommendations on the diagnosis and clinical trial eligibility criteria for patients with renal medullary carcinoma. Clin Genitourin Cancer. 2018 Sep 12. pii: S1558-7673(18)30384-7. doi: 10.1016/j.clgc.2018.09.005. [Epub ahead of print]PMID:30287223.
Mullen EA, Chi YY, Hibbits E, Anderson JR, Steacy KJ, Geller JI, Green DM, Khanna G, Malogolowkin MH, Grundy PE, Fernandez CV and Dome JS. Impact of surveillance imaging modality on survival after recurrence in patients with Wilms tumor: A Report from the Children’s Oncology Group. J Clin Oncol. 2018 Oct 18. doi: 10.1200/JCO.18.00076. [Epub ahead of print] PMID:30335557.
Cajaiba MM. Dyer , Geller JI, Jennings LJ, George D, Kirschmann D, Rohan SM, Cost N, Khanna G, Mullen EA, Dome JS, Fernandez CV, Perlman EJ. The Classification of Pediatric and Young Adult Renal Cell Carcinomas Registered on the Children’s Oncology Group (COG) Protocol AREN03B2 Following Focused Genetic Testing. Cancer. 2018 Aug;124(16):3381-3389. doi: 10.1002/cncr.31578. Epub 2018 Jun 15. PMID:29905933
Friedman JM, Bombard Y, Cornel M, Fernandez CV, Junker AK, Plon SE, Stark Z, and Knoppers BM for the Paediatric Task Team of the Global Alliance for Genomics and Health Regulatory and Ethics Works team. Genome-wide Sequencing in Acutely-Ill Infants: Genome Medicine’s Critical Applicaiton? Genetics in Medicine. 2018 Jun 12. doi: 10.1038/s41436-018-0055-z. [Epub ahead of print] PMID:29895853.
Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Grundy PE, Fernandez CV, Dome JS on behalf of the AREN0533 Study Committee. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018 Jun 1;36(16):1564-1570. doi: 10.1200/JCO.2017.77.1931. Epub 2018 Apr 16.PMID:29659330.
Wolf SM, Scholtes E, Koenig BA, Petersen GM, Berry SA, Beskow LM, Daly MB, Fernandez CV, Green RC, LeRoy BS, Lindor NM, O’Rourke PP, Radecki Breitkopf C, Rothstein MA, Van Ness B, and Wilfond BS. Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants. J Law Med Ethics. 2018 Mar;46(1):87-109. doi: 10.1177/1073110518766024. Epub 2018 Mar 27. PMID: 30008546
V Rahimzadeh, C Schickhardt, BM Knoppers, K Sénécal, DF Vears, CV Fernandez, S Pfister, S Plon, EW Clayton, S Terry, J Williams, MS Williams, M Cornel, JM Friedman. Key Implications of Data Sharing in Pediatric Genomics: Points to Consider for KIDS. JAMA Pediatrics. 2018 May 1;172(5):476-481. doi: 10.1001/jamapediatrics.2017.5500. PMID: 29554172
Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer F, Withycombe J, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS. Outcome and prognostic factors in stage III Favorable Histology Wilms Tumor (FHWT). A report from the Children’s Oncology Group Study AREN0532. J Clin Oncol. 2018 Jan 20;36(3):254-261. doi: 10.1200/JCO.2017.73.7999. Epub 2017 Dec 6.PMID: 29211618.